The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery

NCT02281981 | Withdrawn

• 1 other identifier: Curcumin
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Arterial Stiffness: As a recognized independent indicator of cardiovascular risk, maintaining low levels of arterial stiffening is important to cardiovascular health. Increases in arterial stiffening results in elevated systolic and mean pressure and it is correlated with various cardiovascular conditions such as left ventricular hypertrophy, ischaemic heart disease, and myocardial infarction. In contrast, decreased arterial stiffness improves ventricular-vascular coupling, ejection fraction, and cardiac output. Arterial stiffness is linked to inflammation and oxidative stress. Both inflammation and oxidative stress are elevated during DOMS (delayed onset muscle soreness), a state brought on by muscle damage often incurred during strenuous exercise. Recent studies have shown that a single bout of eccentric exercise can produce acute arterial stiffness during recovery. However, anti-oxidants/anti-inflammatories may be effective in reducing the extent of damage by decreasing oxidation and inflammation. Curcumin is a powerful antioxidant that could act as an anti-inflammatory and diminish the effects of the downhill run. In addition, eccentric damage generates a prophylactic protection lasting up to six weeks. The nature of the downhill run is primarily eccentric in nature. Therefore, repeated bouts may have diminished DOMS development. Any reduction in stress by either the prophylactic repeated bout effect or the Curcumin supplement, should attenuate the increase in arterial stiffness due to the reduction in inflammation.

Conditions

Vascular Stiffness

Outcome Measures

Primary Outcomes (2)

• Arterial Stiffness

  This will be measured using arterial tonometry

  Every 24 hr up to 72hr post baseline

• Blood measures of inflammation and muscle damage

  Interleukin-6, highsensitivity C-reactive protein, Creatine Kinase

  Every 24 hr up to 72hr post baseline

Secondary Outcomes (1)

• Delayed onset muscle soreness

  Every 24 hr up to 72hr post baseline

Study Arms (2)

Curcumin supplement

EXPERIMENTAL

200 mg, curcuminoids, 7d of supplementation in capsular form

Dietary Supplement: Curcumin

Placebo

PLACEBO COMPARATOR

sucrose, capsular

Dietary Supplement: Placebo

Interventions

Curcumin DIETARY_SUPPLEMENT

333mg CurcuWin OAHTCUR002-2014

Also known as: Tumeric extract

Curcumin supplement

Placebo DIETARY_SUPPLEMENT

OAHTCUR005-2014

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects will be male or female
• yr - 45yr
• Free from any known or suspected chronic conditions.
• General health and suitability to participate in an exercise/health research study will be confirmed through use of the PAR-Q+ screening questionnaire

You may not qualify if:

• Any participant who has a positive answer to a screening question will be required to seek physician approval prior to any physical exercise.
• During baseline anthropometric assessment we will confirm that participants all fall within a typical BMI range (20-30 kg/m2) of either "normal" weight or "overweight", but not "underweight" or "obese".
• Persons who take cardiovascular medications, metabolic medications, smoke cigarettes, excessively consume alcohol, are prone to heartburn, or have a previous diagnosis of hyperlipidemia or hyperinsulemia will also be excluded

Sponsors & Collaborators

• University of Prince Edward Island: lead
• OmniActive Health Technologies: collaborator

MeSH Terms

Interventions

Curcumin

Intervention Hierarchy (Ancestors)

Diarylheptanoids; Heptanes; Alkanes; Hydrocarbons, Acyclic; Hydrocarbons; Organic Chemicals; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic

Study Officials

• Jamie F Burr, PhD

  UPEI

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: October 29, 2014
• First Posted: November 4, 2014
• Study Start: January 1, 2014
• Primary Completion: January 1, 2015
• Study Completion: January 1, 2016
• Last Updated: June 23, 2022

Record last verified: 2022-06